H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Provention Bio to $16 from $18 and keeps a Buy rating on the shares. The target is lowered to reflect the impact of the dilution from the issuance of stock to Sanofi, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRVB: